United Treatment Centers (OTCMKTS:POTN) & 10x Genomics (NASDAQ:TXG) Head-To-Head Analysis

United Treatment Centers (OTCMKTS:POTN) and 10x Genomics (NASDAQ:TXG) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Valuation & Earnings

This table compares United Treatment Centers and 10x Genomics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Treatment Centers	N/A	N/A	N/A	N/A	N/A
10x Genomics	$610.78 million	3.39	-$182.63 million	($0.62)	-26.42

United Treatment Centers has higher earnings, but lower revenue than 10x Genomics.

Insider & Institutional Ownership

84.7% of 10x Genomics shares are held by institutional investors. 0.2% of United Treatment Centers shares are held by company insiders. Comparatively, 10.0% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for United Treatment Centers and 10x Genomics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Treatment Centers	0	0	0	0	0.00
10x Genomics	3	9	4	0	2.06

10x Genomics has a consensus price target of $15.81, indicating a potential downside of 3.49%. Given United Treatment Centers’ higher possible upside, research analysts plainly believe United Treatment Centers is more favorable than 10x Genomics.

Profitability

This table compares United Treatment Centers and 10x Genomics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
United Treatment Centers	N/A	N/A	N/A
10x Genomics	-11.89%	-11.50%	-8.93%

Summary

10x Genomics beats United Treatment Centers on 5 of the 9 factors compared between the two stocks.

About United Treatment Centers

Diamond Wellness Holdings Inc., through its subsidiaries, engages in the development and sale of hemp-derived cannabidiol (CBD) oil products. It offers flavored and unflavored oils; vaping pens and additives; edibles, such as chewable gummies and lollipops; capsules; beverage energy/relaxation shots; topical application creams in various concentrations; dog and cat wellness products in various dosages and delivery formats; skin care, bath, and body products; and hemp flowers. The company provides its products under various brands, including Diamond CBD, Chill, Relax, MediPets, and Meds BioTech, as well as various other brands. It sells its products through distributors and resellers, as well as through its Website. The company was formerly known as PotNetwork Holdings, Inc. Diamond Wellness Holdings Inc. is based in Fort Lauderdale, Florida.

About 10x Genomics

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.